|
1
|
Ostrom QT, Gittleman H, Liao P, et al:
CBTRUS statistical report: primary brain and central nervous system
tumors diagnosed in the United States in 2007–2011. Neuro Oncol.
16:(Suppl 4). iv1–iv63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Verdecchia A, De Angelis G and Capocaccia
R: Estimation and projections of cancer prevalence from cancer
registry data. Stat Med. 21:3511–3526. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weller M: Novel diagnostic and therapeutic
approaches to malignant glioma. Swiss Med Wkly.
141:w132102011.PubMed/NCBI
|
|
4
|
McNamara MG, Sahebjam S and Mason WP:
Emerging biomarkers in glioblastoma. Cancers (Basel). 5:1103–1119.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stupp R, Hegi ME, Mason WP, et al:
European Organisation for Research and Treatment of Cancer Brain
Tumour and Radiation Oncology Groups; National Cancer Institute of
Canada Clinical Trials Group: Effects of radiotherapy with
concomitant and adjuvant temozolomide versus radiotherapy alone on
survival in glioblastoma in a randomised phase III study: 5-year
analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Mason WP, van den Bent MJ, et al:
European Organisation for Research and Treatment of Cancer Brain
Tumor and Radiotherapy Groups; National Cancer Institute of Canada
Clinical Trials Group: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh SK, Hawkins C, Clarke ID, et al:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singh SK, Clarke ID, Terasaki M, et al:
Identification of a cancer stem cell in human brain tumors. Cancer
Res. 63:5821–5828. 2003.PubMed/NCBI
|
|
11
|
Lim SH, Jang J, Park JO, et al:
CD133-positive tumor cell content is a predictor of early
recurrence in colorectal cancer. J Gastrointest Oncol. 5:447–456.
2014.PubMed/NCBI
|
|
12
|
Mizugaki H, Sakakibara-Konishi J, Kikuchi
J, et al: CD133 expression: a potential prognostic marker for
non-small cell lung cancers. Int J Clin Oncol. 19:254–259. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hashimoto K, Aoyagi K, Isobe T, et al:
Expression of CD133 in the cytoplasm is associated with cancer
progression and poor prognosis in gastric cancer. Gastric Cancer.
17:97–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rappa G, Fodstad O and Lorico A: The stem
cell-associated antigen CD133 (Prominin-1) is a molecular
therapeutic target for metastatic melanoma. Stem Cells.
26:3008–3017. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang CH, Chiou SH, Chou CP, et al:
Photothermolysis of glioblastoma stem-like cells targeted by carbon
nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine.
7:69–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Clément V, Marino D, Cudalbu C, et al:
Marker-independent identification of glioma-initiating cells. Nat
Methods. 7:224–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Clément V, Dutoit V, Marino D, Dietrich PY
and Radovanovic I: Limits of CD133 as a marker of glioma
self-renewing cells. Int J Cancer. 125:244–248. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Sakariassen PØ, Tsinkalovsky O, et
al: CD133 negative glioma cells form tumors in nude rats and give
rise to CD133 positive cells. Int J Cancer. 122:761–768. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Beier D, Hau P, Proescholdt M, et al:
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show
differential growth characteristics and molecular profiles. Cancer
Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hermansen SK, Christensen KG, Jensen SS
and Kristensen BW: Inconsistent immunohistochemical expression
patterns of four different CD133 antibody clones in glioblastoma. J
Histochem Cytochem. 59:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeppernick F, Ahmadi R, Campos B, et al:
Stem cell marker CD133 affects clinical outcome in glioma patients.
Clin Cancer Res. 14:123–129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Immervoll H, Hoem D, Sakariassen PØ,
Steffensen OJ and Molven A: Expression of the ‘stem cell marker’
CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC
Cancer. 8:482008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thon N, Damianoff K, Hegermann J, et al:
Presence of pluripotent CD133+ cells correlates with
malignancy of gliomas. Mol Cell Neurosci. 43:51–59. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Beier D, Wischhusen J, Dietmaier W, et al:
CD133 expression and cancer stem cells predict prognosis in
high-grade oligodendroglial tumors. Brain Pathol. 18:370–377. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pallini R, Ricci-Vitiani L, Banna GL, et
al: Cancer stem cell analysis and clinical outcome in patients with
glioblastoma multiforme. Clin Cancer Res. 14:8205–8212. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Christensen K, Schrøder HD and Kristensen
BW: CD133 identifies perivascular niches in grade II-IV
astrocytomas. J Neurooncol. 90:157–170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bidlingmaier S, Zhu X and Liu B: The
utility and limitations of glycosylated human CD133 epitopes in
defining cancer stem cells. J Mol Med (Berl). 86:1025–1032. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Florek M, Haase M, Marzesco AM, et al:
Prominin-1/CD133, a neural and hematopoietic stem cell marker, is
expressed in adult human differentiated cells and certain types of
kidney cancer. Cell Tissue Res. 319:15–26. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jordan M, Schallhorn A and Wurm FM:
Transfecting mammalian cells: optimization of critical parameters
affecting calcium-phosphate precipitate formation. Nucleic Acids
Res. 24:596–601. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shmelkov SV, St Clair R, Lyden D and Rafii
S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 37:715–719.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Plumb JA, Milroy R and Kaye SB: Effects of
the pH dependence of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide-formazan absorption on chemosensitivity determined by a
novel tetrazolium-based assay. Cancer Res. 49:4435–4440.
1989.PubMed/NCBI
|
|
32
|
Campos B and Herold-Mende CC: Insight into
the complex regulation of CD133 in glioma. Int J Cancer.
128:501–510. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu A, Oh S, Wiesner SM, et al: Persistence
of CD133+ cells in human and mouse glioma cell lines:
detailed characterization of GL261 glioma cells with cancer stem
cell-like properties. Stem Cells Dev. 17:173–184. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Platet N, Liu SY, Atifi ME, et al:
Influence of oxygen tension on CD133 phenotype in human glioma cell
cultures. Cancer Lett. 258:286–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Christensen K, Aaberg-Jessen C, Andersen
C, Goplen D, Bjerkvig R and Kristensen BW: Immunohistochemical
expression of stem cell, endothelial cell, and chemosensitivity
markers in primary glioma spheroids cultured in serum-containing
and serum-free medium. Neurosurgery. 66:933–947. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Corbeil D, Röper K, Hellwig A, et al: The
human AC133 hematopoietic stem cell antigen is also expressed in
epithelial cells and targeted to plasma membrane protrusions. J
Biol Chem. 275:5512–5520. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miraglia S, Godfrey W, Yin AH, et al: A
novel five-transmembrane hematopoietic stem cell antigen:
isolation, characterization, and molecular cloning. Blood.
90:5013–5021. 1997.PubMed/NCBI
|
|
38
|
Mizrak D, Brittan M and Alison M: CD133:
molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fargeas CA, Huttner WB and Corbeil D:
Nomenclature of prominin-1 (CD133) splice variants - an update.
Tissue Antigens. 69:602–606. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jaszai J, Fargeas CA, Florek M, Huttner WB
and Corbeil D: Focus on molecules: prominin-1 (CD133). Exp Eye Res.
85:585–586. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fargeas CA, Joester A, Missol-Kolka E,
Hellwig A, Huttner WB and Corbeil D: Identification of novel
Prominin-1/CD133 splice variants with alternative C-termini and
their expression in epididymis and testis. J Cell Sci.
117:4301–4311. 2004. View Article : Google Scholar : PubMed/NCBI
|
